BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Free Report) had its target price decreased by Leerink Partners to $27.00 in a research note released on Thursday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock. A number of other research firms have also recently commented on BBOT. Weiss Ratings restated a “sell (d-)” rating on […]

Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price lifted by Guggenheim from $135.00 to $170.00 in a report released on Monday, Marketbeat Ratings reports. Guggenheim currently has a buy rating on the stock. Several other analysts have also recently commented on the company. B. Riley Financial raised their target price on Kymera Therapeutics […]

Maplight Therapeutics (NASDAQ:MPLT – Free Report) had its target price trimmed by Needham & Company LLC from $45.00 to $43.00 in a research report sent to investors on Monday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock. Other equities analysts also recently issued research reports about the stock. Wolfe Research […]